糖尿病心肌病1例报道并文献复习
Diabetes Cardiomyopathy: A Case Report and Literature Review
DOI: 10.12677/acm.2025.1561812, PDF,   
作者: 沙嘉玥, 陈 澍, 夏培金*：镇江市中西医结合医院内分泌科，江苏 镇江
关键词: 糖尿病心肌病；心力衰竭；诊断；Diabetic Cardiomyopathies； Heart Failure； Diagnosis
摘要: 糖尿病性心肌病(DCM)是一种起病隐匿，长期处于慢性高血糖状态的心肌功能障碍性疾病，其主要特征是心肌细胞肥大、纤维化进展、心室功能受损。早期表现为心肌结构及功能改变，最终导致心力衰竭、心律失常和心源性休克，严重者甚至导致心源性猝死。本文就DCM进行了病例报道和文献复习，为DCM的诊治提供思路，避免延治误治。
Abstract: Diabetes cardiomyopathy (DCM) is a kind of myocardial dysfunction disease with concealed onset and chronic hyperglycemia for a long time. Its main characteristics are cardiomyocyte hypertrophy, fibrosis progression, and impairment of ventricular function. Early manifestations are changes in myocardial structure and function, which eventually lead to heart failure, arrhythmia, cardiogenic shock, and even sudden cardiac death in severe cases. This article provides case reports and literature review on DCM, providing ideas for the diagnosis and treatment of DCM and avoiding delayed treatment and mistreatment.
文章引用：沙嘉玥, 陈澍, 夏培金. 糖尿病心肌病1例报道并文献复习[J]. 临床医学进展, 2025, 15(6): 962-967. https://doi.org/10.12677/acm.2025.1561812

参考文献

[1] World Health Organization (2020) The Top 10 Causes of Death.
https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
[2] Kannel, W.B. and McGee, D.L. (1979) Diabetes and Cardiovascular Disease. Framingham Study. JAMA, 241, 2035-2038.
[3] Huo, J., Feng, Q., Pan, S., Fu, W., Liu, Z. and Liu, Z. (2023) Diabetic Cardiomyopathy: Early Diagnostic Biomarkers, Pathogenetic Mechanisms, and Therapeutic Interventions. Cell Death Discovery, 9, Article No. 256. [Google Scholar] [CrossRef] [PubMed]
[4] Graczyk, P., Dach, A., Dyrka, K. and Pawlik, A. (2024) Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus. International Journal of Molecular Sciences, 25, Article No. 5027. [Google Scholar] [CrossRef] [PubMed]
[5] Nakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., et al. (2022) Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. International Journal of Molecular Sciences, 23, Article No. 3587. [Google Scholar] [CrossRef] [PubMed]
[6] Seferović, P.M. and Paulus, W.J. (2015) Clinical Diabetic Cardiomyopathy: A Two-Faced Disease with Restrictive and Dilated Phenotypes. European Heart Journal, 36, 1718-1727. [Google Scholar] [CrossRef] [PubMed]
[7] 徐勇, 马秀梅. 糖尿病心肌病的早期诊断与治疗策略[J]. 西南医科大学学报, 2023, 46(5): 387.
[8] Hayat, S.A., Patel, B., Khattar, R.S. and Malik, R.A. (2004) Diabetic Cardiomyopathy: Mechanisms, Diagnosis and Treatment. Clinical Science, 107, 539-557. [Google Scholar] [CrossRef] [PubMed]
[9] Stanton, A.M., Vaduganathan, M., Chang, L., Turchin, A., Januzzi, J.L. and Aroda, V.R. (2021) Asymptomatic Diabetic Cardiomyopathy: An Underrecognized Entity in Type 2 Diabetes. Current Diabetes Reports, 21, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
[10] Kiencke, S., Handschin, R., von Dahlen, R., Muser, J., Brunner‐LaRocca, H.P., Schumann, J., et al. (2010) Pre‐Clinical Diabetic Cardiomyopathy: Prevalence, Screening, and Outcome. European Journal of Heart Failure, 12, 951-957. [Google Scholar] [CrossRef] [PubMed]
[11] 仲崇琦. 超声技术在糖尿病心肌病中的研究进展[J]. 心血管病防治知识, 2024, 6(14): 141-143.
[12] Aneja, A., Tang, W.H.W., Bansilal, S., Garcia, M.J. and Farkouh, M.E. (2008) Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options. The American Journal of Medicine, 121, 748-757. [Google Scholar] [CrossRef] [PubMed]
[13] Fang, Z.Y., Schull-Meade, R., Leano, R., Mottram, P.M., Prins, J.B. and Marwick, T.H. (2005) Screening for Heart Disease in Diabetic Subjects. American Heart Journal, 149, 349-354. [Google Scholar] [CrossRef] [PubMed]
[14] Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Drazner, M.H., et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 128, 1810-1852. [Google Scholar] [CrossRef] [PubMed]
[15] Ledwidge, M., Gallagher, J., Conlon, C., Tallon, E., O’Connell, E., Dawkins, I., et al. (2013) Natriuretic Peptide-Based Screening and Collaborative Care for Heart Failure: The Stop-Hf Randomized Trial. JAMA, 310, 66-74. [Google Scholar] [CrossRef] [PubMed]
[16] Huang, K., Luo, X., Liao, B., Li, G. and Feng, J. (2023) Insights into SGLT2 Inhibitor Treatment of Diabetic Cardiomyopathy: Focus on the Mechanisms. Cardiovascular Diabetology, 22, Article No. 86. [Google Scholar] [CrossRef] [PubMed]
[17] Voors, A.A., Angermann, C.E., Teerlink, J.R., Collins, S.P., Kosiborod, M., Biegus, J., et al. (2022) The SGLT2 Inhibitor Empagliflozin in Patients Hospitalized for Acute Heart Failure: A Multinational Randomized Trial. Nature Medicine, 28, 568-574. [Google Scholar] [CrossRef] [PubMed]
[18] Maselli, D.B. and Camilleri, M. (2020) Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. In: Islam, Md.S., Ed., Diabetes: From Research to Clinical Practice, Springer International Publishing, 171-192. [Google Scholar] [CrossRef] [PubMed]
[19] Bonaventura, A., Carbone, S., Dixon, D.L., Abbate, A. and Montecucco, F. (2019) Pharmacologic Strategies to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Focus on SGLT‐2 Inhibitors and GLP‐1 Receptor Agonists. Journal of Internal Medicine, 286, 16-31. [Google Scholar] [CrossRef] [PubMed]
[20] Nauck, M.A., Quast, D.R., Wefers, J. and Meier, J.J. (2021) GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes—State-of-the-Art. Molecular Metabolism, 46, Article ID: 101102. [Google Scholar] [CrossRef] [PubMed]
[21] Solomon, S.D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., et al. (2012) The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase 2 Double-Blind Randomised Controlled Trial. The Lancet, 380, 1387-1395. [Google Scholar] [CrossRef] [PubMed]
[22] Burnier, M., Bakris, G. and Williams, B. (2019) Redefining Diuretics Use in Hypertension: Why Select a Thiazide-Like Diuretic? Journal of Hypertension, 37, 1574-1586. [Google Scholar] [CrossRef] [PubMed]
[23] Liu, W., Gong, W., He, M., Liu, Y., Yang, Y., Wang, M., et al. (2018) Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats. Journal of Diabetes Research, 2018, Article ID: 9232065. [Google Scholar] [CrossRef] [PubMed]
[24] 金涛. 非奈利酮在糖尿病心肌病中的作用及其机制研究[D]: [博士学位论文]. 济南: 山东大学, 2023.

为你推荐